> MedImmune has agreed to sell its transplant drug CytoGam to ZLB Behring in exchange for $50 million and up to $70 million for achieving a schedule of sales milestones. CytoGam is an antibody therapy designed to protect transplant patients from infections. MedImmune says it's selling CytoGam because it no longer fits its definition of a core product. MedImmune is developing vaccines and drugs for respiratory viruses. Report
> Targacept is reporting mixed results from its late stage trial of the depression therapy mecamylamine taken with citalopram hydrobromide (Celexa). The treatment combination is known as TRIDMAC. The therapy improved symptoms of disease but didn't demonstrate a statistically significant achievement of remission. Release
> Perrigo is recalling 11 million bottles of generic pain relief drugs after finding that some were contaminated with metal fragments. Report
> ActivBiotics has slashed its IPO price to $8 to $10 a share from $12 to $14. Report
> Pharmasset has won a $7.5 million milestone payment from Roche. Report
> A federal jury has ruled against an ophthalmologist who claimed that he was owed a share of the revenue from Lucentis. Report
> Albany Molecular plans to cut 40 jobs at its manufacturing operation in Rensselaer. Report
> Taro Pharmaceuticals has received FDA approval for a generic version of Mobic for osteoarthritis and rheumatoid arthritis. Report
> A U.K. team has used stem cells to restore mice retinas. Report
> An early-stage trial has provided some important proof that gene therapy could be an effective way to fight HIV. Report
> A new study will test the use of stem cells after heart attacks. Report
And Finally….The new focus on stem cell research has persuaded a number of law firms to add it to their list of specialties. Article